English

• 25 Feb, 2022
  Spago Nanomedical receives go-ahead to include patients with pancreatic cancer in the clinical study SPAGOPIX-01
• 23 Feb, 2022
  Spago Nanomedical publishes the annual report for 2021
• 2 Feb, 2022
  Spago Nanomedical year-end report January-December, 2021
• 25 Jan, 2022
  Significantly reduced tumor growth with Tumorad® according to new preclinical results
• 13 Jan, 2022
  Spago Nanomedicals phase 1 study with SpagoPix shows clear contrast enhancement and is expanded into new indications
• 6 Dec, 2021
  Tumorad® shows good safety in preclinical studies
• 2 Dec, 2021
  Second dose group fully recruited in Spago Nanomedical’s phase 1 study with SpagoPix
• 10 Nov, 2021
  Spago Nanomedical interim report January-September 2021
• 10 Nov, 2021
  Spago Nanomedical selects Cmed as its CRO for the first clinical trial with Tumorad®
• 21 Oct, 2021
  Nomination committee appointed for the 2022 Annual General Meeting in Spago Nanomedical